Press "Enter" to skip to content

Biotechnology: Inflection points for success | Dr Narendra Chirmule | TEDxJIPMER


[Music]
today speaking about outside the box I
thought I’d talk a little bit about
inflection points an inflection point is
a point in the curve that changes the
shape of the curve and the factors that
are involved in changing the shape of
the curve as you can see in this slide
come after the shape of the curve has
changed I’ll come to this topic a little
bit later during my talk I started my
career in research in 1982 but I wanted
to do my PhD at the Cancer Research
Institute in peril Bombay this is me in
1982 working on a Apple computer at that
time I did my PhD with dr. mg Dave and
one of the questions he asked me during
my interview for PhD was how does
cervical cancer cause disease and my
true and honest answer at that time was
sir I don’t know the answer but it is
these questions that I feel like
answering is why I’m applying to cancer
Research Institute later on he told me
it is because of this truthful answer
that I got admission into that
prestigious institution the inflection
point that occurred to me in the Cancer
Research Institute the premier Cancer
Research Institute was the project that
I was supposed to work on was developing
a leprosy vaccine only later in my
career did I actually learn that leprosy
is one of those diseases where all
aspects of immunology can be studied so
I learned a lot of immunology during my
Cornell University Medical College where
I did my postdoctoral fellowship and I
had an opportunity to work on the
pathogenesis of
ADEs 1986-87
the virus had just been discovered the
receptor for the virus was being
discovered how HIV causes immune
suppression was being discovered Cornell
was the epicenter of this study and I
was in the midst I was learning virus
immunology like there’s no tomorrow
a huge inflection point in my career I
then got an opportunity to work with one
of the premier institutions in the world
University of Pennsylvania with Jim
Wilson to work on gene therapy and this
was 1996 the field of gene therapy had
reached astronomical Heights the gene
for cystic fibrosis had been cloned and
people were starting to think about
curing genetic diseases with gene
therapy using adenoviral vectors what is
adenovirus it’s the common cold the way
you do gene therapy is you take the
virus take out the genes of the virus
replace them with the gene that you want
to transmit into your lung infect the
lungs in this case with adenovirus and
lo and behold your normal gene is
expressed in your lungs we did a
clinical trial on a similar deficiency
called ornithine transcarbamylase it’s a
deficiency of a gene in patients when
they don’t have this gene the children
die of brain damage that is because this
enzyme is required to convert protein
into urea in the absence of this enzyme
the metabolism changes and the protein
converts to ammonia which goes to the
brain and the children die of brain
encephalopathy the the disease is very
good for treatment of gene therapy
because it’s a single gene defect
meaning if you correct this gene you
will correct the disease it is localized
to the liver and the mouse model of this
disease has been corrected so we
undertook the trial where he we used
this adenovirus
put the normal OTC gene into the virus
and gave patients the intravenous
injection of this virus which entered
the liver and this patient now would
have normal OTC gene and therefore
should be corrected of this disease the
goal was to establish safety of the
adenovirus
vector what happened this is a graph
which on the y axis measures toxicity
which is safety and on the x axis is
just the increasing patient number when
we measure toxicity you generally expect
a linear curve every patient will get a
little bit more toxicity but that did
not happen with this with this trial the
first 18 patients had very very minimal
adverse events with safety adverse
events the 19th patient died it changed
the field the trial was stopped post
mortem of this child showed it was a
multi-organ failure with insult to the
bone marrow to the liver to lungs to
brain and the spleen in scientific team
clinical terms it’s called disseminated
intravascular coagulopathy it’s like a
septic shock the lessons we learned from
this trial failed trial was that the
clinical protocol is actually a contract
with the patient and the regulator’s it
is very critical to report every event
in the trial and every result that leads
to the trial and informed consents
require 3rd party plugins
other lessons but these are the three
main ones that academic institutions
learnt during the development of
clinical trials in an academic setting
it was a turning point inflection point
in the field of gene therapy everything
came to a crashing halt
Jim Wilson is a pioneer in the field of
gene therapy he was the director of the
Institute or director of the clinical
trial that just failed magnanimously he
didn’t stop hard there he moved from
adenoviruses to what are called
adeno-associated virus these viruses and
an associated viruses don’t cause any
known human disease and therefore they
could have been or they may be a very
good vector for transmitting genes and
they don’t they may not cause
inflammation like adenovirus did and he
discovered a whole range of different
viruses which could be a V viruses which
could be used using these AEV viruses in
the next decade and University of
Pennsylvania there was a revolution in
the field of gene therapy literally this
year in 2018 gene Bennett with a team of
large and beautiful individuals have
treated and cured this disease of
patients having retinal pigment
epithelial gene defect and they have
it’s a cure for this kind of blindness
using gene therapy using AAV vectors
Kathy hi she has used factor 8 and
factor 9 and they’re doing clinical
trials in late phase which can be a
potential core cure for Hugh Murphy Lee
axe all of these beautiful results of
gene therapy using vectors surface
because of that inflection point that
happened a decade ago
I’m a then moved to Merck from
University of Pennsylvania in 2000 there
I had an unusual experience by that time
about 10 years experience in Cornell
University Medical College learning
about HIV and HIV pathogenesis but five
or six years experience working on
adenoviral vectors to transduce genes
that’s what my experience was at that
point and Mark was interested in
developing an HIV vaccine which is for
preventing HIV using adenoviral vectors
it’s a very interesting design in 2007
before we get to the vaccine itself one
slide on very basic vaccine immunology
we all get vaccinated with all kinds of
vaccines and we’ve been vaccinated
vaccines have been available for the
last 60 70 80 years we get vaccinated
with hepatitis A hepatitis B DTP polio
all kinds of vaccines most of the
vaccines that we get vaccinated against
elicit an antibody response by the body
which means our b-cells which is one
type of immune response
indeed secretes antibodies which then
protect us from getting infected with
that virus with HIV it’s slightly
different HIV enters inside the cell and
stays inside the cell so the thought in
2000-2007 timeframe was if there’s a
virus inside the cell you need to
activate another part of the immune
system which is called the T cell and
that T cell should be able to kill the
virus infect itself that was the theory
of developing this vaccine for which we
did a clinical trial again using
adenovirus the same common cold virus
but instead of putting a gene in it what
we did was we we put the gene for HIV
gag which is one of the viral HIV viral
proteins with the theory that it will
activate T cells in the body which are
specific to HIV and they will kill the
virus specific T cells now this study
was a placebo controlled blinded trial
in subjects with high risk behavior the
goal of the vaccine was to reduce the
probability of getting HIV infection and
this is a result a dramatically
unexpected result in the field of
vaccinology patients who were infected
shown in the red bar had a higher
probability of getting HIV infection
than the controls
very unexpected result this is exactly
opposite of what you would expect a
vaccine to do what lesson did we learn
we learnt that human non-human primates
on which all the previous work had been
done where it showed that if you
activate a t-cell response you can
actually prevent monkeys from getting
infected
that model doesn’t work in humans human
immune responses us some there’s
something different about human
responses that it doesn’t mimic what we
see in animals when we designed the
clinical trial new kinds of clinical
trials have been now started to be used
for HIV which is what I call adaptive
designs you do a particular portion of
the trial you observe something you
change the design and then you observe
something else and then you change the
design this way you reduce the risk to
the patient over time and then finally
the use of social and behavioral
research during vaccine studies so what
happened to the field we still don’t
have a vaccine for HIV I’ve been
fortunate to be part of the NIH s
vaccine committee that I’m part of the
process to review proposals for vaccine
research but this slide shows for the
first 20 years 1980 to about 2000 the
whole focus of HIV vaccines was to
develop classical vaccines develop an
antibody response and you will protect
against it against HIV many trials were
tried and many failed in 2000 to 2007
the field started focusing on it is the
t-cell we need the t-cell to activate
the vaccine that study failed we just I
just showed you the data on that so now
the thinking is it is not that it is the
combination of T and B cells that you
need to get a protective vaccines time
will tell whether such a vaccine will be
developed for the world very challenging
problem fast forward to 2008 to 2018
India biotechnology sector valued at
almost a bill 11 billion dollars today
293 billion dollars worldwide
growth rate of 20% led the charli’s the
charge in biopharmaceutical industry in
farm biopharmaceutical industry is
developing at a very high rate in 2015
after almost 30 years of spending my
spending in the US and various
institutions I decide that I want to
come back to India and help the process
in developing biologics I was very
attracted by the mission statement of
bio Khan which is to develop affordable
healthcare and we all know Kiran wisdom
that Shah is an inspiration leader and
Arun Chandavarkar who’s the CEO of
visionary leaders for the company on
this mission I joined biocon drug
development is extremely complicated and
extremely expensive requires mechanism
of action you need to demonstrate
efficacy and you need to show safety
that gives you a regulatory approval
however to reach the patient you need to
have value and you need to have access
patients need to have access to this
drug so last year I’m proud to say that
bio corn got the first approval ever of
any company in India by the FDA
trastuzumab which is the drug for breast
cancer and that was a huge
accomplishment bye-bye oh God thank you
the huge team of people have done this
work and I’ll end my talk by – two
slides one I talked about the inflection
points in my career that changed the
curve of the shape of my careers curve
like I said inflection points you just
do the things that you are passionate
about and the inflection point will be
behind you you can never focus on an
inflection point it’s never in front of
you it’s always behind you when you do
things an inflection point will appear
behind you you can’t think about
inflection points and final slide on
culture is I feel I started off my
career by being truthful and honest and
I think these are the essential elements
of cultures of organizations people
individual societies that’ll make things
happen and we need lots of inflection
points
to make things happen thank you very
much [Applause]
Please follow and like us: